Deliberative Processes by Health Technology Assessment Agencies: A Reflection on Legitimacy, Values and Patient and Public Involvement Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe".
Decision-Making
Ethics
Health Technology Assessment
Multicriteria Approaches
Patient and Public Involvement (PPI)
Journal
International journal of health policy and management
ISSN: 2322-5939
Titre abrégé: Int J Health Policy Manag
Pays: Iran
ID NLM: 101619905
Informations de publication
Date de publication:
14 03 2021
14 03 2021
Historique:
received:
21
12
2019
accepted:
24
03
2020
pubmed:
3
7
2020
medline:
14
9
2021
entrez:
3
7
2020
Statut:
epublish
Résumé
Legitimacy of deliberation processes leading to recommendations for public financing or clinical practice depends on the data considered, stakeholders involved and the process by which both of these are selected and organised. Oortwijn et al provides an interesting exploration of processes currently in place in health technology assessment (HTA) agencies. However, agencies are struggling with core issues central to their legitimacy that goes beyond the procedural exploration of Oortwijn et al, such as: how processes reflect the mission and values of the agencies? How they ensure that recommendations are fair and reasonable? Which role should be given to public and patient involvement? Do agencies have a positive impact on the healthcare system and the populations served? What are the drivers of their evolution? We concur with Culyer commentary on the need of learning from doing what works best and that a reflection is indeed needed to "enhance the fairness and legitimacy of HTA."
Identifiants
pubmed: 32610794
doi: 10.34172/ijhpm.2020.46
pmc: PMC8167272
doi:
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
228-231Commentaires et corrections
Type : CommentOn
Informations de copyright
© 2021 The Author(s); Published by Kerman University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/ licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Références
Int J Technol Assess Health Care. 2017 Jan;33(4):504-520
pubmed: 29019295
Value Health. 2017 Feb;20(2):256-260
pubmed: 28237205
Int J Health Policy Manag. 2019 Mar 10;8(6):337-352
pubmed: 31256566
Int J Health Policy Manag. 2020 Jun 01;9(6):263-265
pubmed: 32613796
Cost Eff Resour Alloc. 2018 Nov 9;16(Suppl 1):54
pubmed: 30455613
Philos Public Aff. 1997 Fall;26(4):303-50
pubmed: 11660435
Nature. 2019 Oct;574(7777):163-166
pubmed: 31597977
Value Health. 2019 Jan;22(1):13-20
pubmed: 30661627
Int J Health Policy Manag. 2020 Jan 01;9(1):27-33
pubmed: 31902192
BMJ. 2013 May 14;346:f2614
pubmed: 23674136
Allergy Asthma Clin Immunol. 2020 Mar 18;16:20
pubmed: 32206067
Health Aff (Millwood). 2008 May-Jun;27(3):759-69
pubmed: 18474969
Lancet. 2017 Jun 17;389(10087):2368-2369
pubmed: 30199663
Int J Health Policy Manag. 2016 May 16;5(8):501-505
pubmed: 27694664